BACKGROUND: Low skeletal muscle radiodensity (SMD) is related to higher mortality in several cancers, but the association with colorectal cancer (CRC) prognosis is unclear. METHODS: This observational study included 3262 men and women from the Kaiser Permanente Northern California population diagnosed between 2006 and 2011 with AJCC stages I to III CRC. The authors evaluated hazard ratios (HRs) of low SMD for all-cause and CRC-specific mortality, assessed by computed tomography using optimal stratification, compared with patients with normal SMD. They also evaluated the cross-classification of categories of low versus normal SMD and muscle mass (MM) with outcomes. RESULTS: The median follow-up was 6.9 years. Optimal stratification cutpoints for SMD were 32.5 in women and 35.5 in men. In multivariate-adjusted analyses, among patients with CRC, those with low SMD demonstrated higher overall (HR, 1.61; 95% confidence interval [95% CI], 1.36-1.90) and CRC-specific (HR, 1.74; 95% CI, 1.38-2.21) mortality when compared with those with normal SMD levels. Patients with low SMD and low MM (ie, sarcopenia) were found to have the highest overall (HR, 2.02; 95% CI, 1.65-2.47) and CRC-specific (HR, 2.54; 95% CI, 1.91-3.37) mortality rates. CONCLUSIONS: In patients with CRC, those with low SMD were found to have elevated risks of disease-specific and overall mortality, independent of MM or adiposity. Clinical practice should incorporate body composition measures into the evaluation of the health status of patients with CRC. Cancer 2018;124:3008-15.
INTRODUCTION
Colorectal cancer (CRC) is the fourth most common cancer diagnosed and the second leading cause of cancer-related mortality in the United States each year. 1 An increasing number of investigations have examined associations between markers of body composition, including skeletal muscle radiodensity (SMD) (ie, the radiodensity of skeletal muscle as measured by computed tomography [CT] ) and cancer prognosis. Sarcopenia (low muscle mass) and myosteatosis (ie, fatty infiltration into muscle that governs SMD) are normal by-products of aging, with the latter related to higher levels of body fat, but are exacerbated by disease and cancer treatments [2] [3] [4] [5] [6] and thus are common in patients with cancer. 7, 8 Several studies have found that low SMD is associated with a poorer cancer prognosis in general 9 and more specifically in patients with lung, 10 breast, 11 pancreatic, 10, 12 and ovarian 13 cancers. However, the influence of SMD in patients with CRC is unclear.
Findings to date have been highly mixed. Boer et al noted no association between either psoas or abdominal SMD and survival in 91 patients with resectable colon cancer, 14 although Blauwhoff-Buskermolen et al reported a significant association between abdominal SMD and overall survival in 67 patients with metastatic CRC but only after multiple adjustment. 15 By contrast, among 322 patients with operable primary CRC, McSorley et al found a significant association between SMD and disease-specific survival in univariate analysis but no significant association after multiple adjustment. 16 Malietzis et al reported nonsignificant, elevated associations between low abdominal SMD and overall and disease-specific survival in 805 patients with CRC, 17 whereas Sabel et al found significant associations of psoas-area SMD and both disease-specific and overall survival in 302 patients with colon cancer. 18 Because low SMD has been related to a higher systemic inflammatory response, 16, 19 metabolic dysregulation, 20, 21 and postsurgical complications, 14 we would expect low SMD to be related to poorer prognosis in patients with CRC. However, associations in previous studies, although suggestive, appear equivocal due in large part to small study sizes. Furthermore, as indicated, methods of body composition assessment differed across studies, thereby impeding direct comparison.
Therefore, using CT scans that were collected as a routine part of clinical care to help diagnose patients with CRC, as well as electronic medical record (EMR) data within the Kaiser Permanente Northern California (KPNC) population, we evaluated body composition and examined the effect of SMD on overall and CRC-specific mortality in 3262 patients with AJCC stage I to III CRC who were diagnosed at KPNC between 2006 and 2011. CT scans assessed at the third lumbar vertebra (L3) were used because of the high correlation of L3 with wholebody values. 22 We further considered the combined influence of low SMD and low muscle mass (MM) on CRC outcomes.
MATERIALS AND METHODS

Study Population
The study population consisted of all patients aged 18 to 80 years from KPNC who were diagnosed with stage I to stage III invasive CRC from 2006 through 2011, whose cancer was confirmed by CT, who underwent surgery, and for whom an electronic weight and height were available at the time of diagnosis. Study participants from this cohort, called the Colorectal-Sarcopenia, Cancer, and Near-term Survival (C-SCANS) cohort, have been previously described. 23 Case ascertainment began in 2006, 1 year after weights routinely became available in the EMR. Approximately one-third of the population of Northern California are members of KP; members represent the underlying population except at socioeconomic extremes. 24 49.9% of study participants were female and 50.1% were male. A waiver of written informed consent was obtained and the study was approved by the institutional review boards of KPNC and the University of Alberta in Edmonton.
Data Collection
Body composition assessment and CT image analysis
Body composition was measured from CT scans (96% contrast vs noncontrast images) taken within 4 months of diagnosis and before treatment with (neoadjuvant or adjuvant) chemotherapy or radiotherapy (median, 0.2 months; range,-2.0 to 3.8 months); 82% of CT scans were obtained before surgery. Using SliceOMatic software (version 5.0; TomoVision, Montreal, Quebec, Canada), a single, trained researcher (J.X.) quantified the cross-sectional area of muscle and adipose in centimeters squared (cm 2 ) at the L3 vertebra, a vertebral landmark previously validated and used in studies of patients with cancer. 25 Single-slice abdominal cross-sectional areas at L3 have been found to be strongly correlated with whole-body volumes of muscle and adipose tissue. 22 Skeletal muscle areas included the rectus abdominis; erector spinae muscles; quadratus lumborum; psoas muscle; and the internal, transverse, and external oblique muscle groups. Using pre-established thresholds of Hounsfield units, 26, 27 we assessed MM, and adipose tissue was segmented to distinguish visceral (intra-abdominal) adipose tissue (VAT), subcutaneous adipose tissue (SAT), and intramuscular adipose tissue (IMAT). SMD was assessed as mean Hounsfield units across muscle area measured at L3. The coefficient of variation for paired observations for SMD was 0.7%.
Clinical variables and endpoints
KPNC cancer registry data and the EMR were reviewed for information regarding prognostic factors, including disease stage, tumor characteristics, surgical procedures, and treatment (chemotherapy, radiotherapy). Data regarding overall and CRC-specific mortality were obtained from the KPNC computerized mortality file, which is comprised of data from the California Department of Public Health Vital Records, the US Social Security Administration, and KPNC utilization data sources. Death from CRC was attributed to an individual if CRC was listed as a cause of death on the death certificate.
Other covariate data EMR data were accessed for information regarding numerous potential confounding variables, including sociodemographic variables (self-reported race is included in the EMR) and smoking history. The Charlson-Deyo Comorbidity Index 28 was used to measure comorbidity. Height and weight were measured by a medical assistant at each medical visit. Partitioned body mass index (BMI) was computed in kilograms per meter squared (kg/m 2 ), removing kilograms of muscle and adipose from the measure of weight; partitioned BMI thus included body weight due to organ, bone, and water weight and was analyzed continuously. The BMI obtained closest to the CT scan (median, 0.0 months) was used in analyses.
Statistical Analysis
We examined covariate distributions by low versus normal SMD, evaluating differences using chi-square tests. Cox proportional hazards regression was used to examine associations between SMD at the time of diagnosis and all-cause and CRC-specific mortality. Follow-up was computed in years from the date of diagnosis.
We initially evaluated tertiles and quartiles of SMD with outcomes. We also explored possible nonlinear relationships between SMD and survival nonparametrically, and by sex, with restricted cubic splines, 29 a technique enabling the specification of a relationship between 2 variables when the function is nonlinear. Tests for nonlinearity used the likelihood ratio test, comparing the model with the linear term with one with linear and cubic spline terms. Because each of these analyses provided strong evidence of a threshold effect of SMD with outcomes, we used optimal stratification 30, 31 to generate sex-specific cutpoints to distinguish patients at higher mortality risk. All subsequent analyses used the dichotomous (low vs normal) SMD variable. We defined patients as having low SMD if values fell below the cutpoints and normal SMD if patient values were greater than or equal to computed cutpoints.
We evaluated time to failure using Kaplan-Meier curves, comparing survival in patients with low and normal SMD using log-rank tests. We subsequently compared Cox models controlling for age, race, and sex with those adjusted in addition for stage of disease, grade, cancer site (distal colon, proximal colon, and rectum), treatment, partitioned BMI, and smoking status. Models were adjusted further for tertiles of VAT and SAT. We specifically did not include IMAT in adjustment to avoid collinearity because SMD levels are governed by IMAT levels.
We simultaneously evaluated associations between SMD and MM to determine independent effects of muscle components on survival. To consider the influence of body phenotypes on outcomes, we further evaluated the cross-classification of dichotomous SMD with normal versus low MM (ie, sarcopenia, the definition based on our previous work 23 , with the reference category including those with both normal SMD and normal MM).
Finally, we conducted analyses of SMD and outcomes stratified by sex, age (<64 years vs 64 years), race, stage of disease, BMI (18.5 to <25, 25 to <30, and 30 kg/m 2 ), Charlson-Deyo Comorbidity Index, treatment status, and CRC site. Heterogeneity in associations in stratified analyses were examined via the introduction of cross-product terms for the dichotomous SMD variable and stratification variables in regression models with evaluation of significance by likelihood ratio chi-square tests. We conducted tests of proportionality with variable by time interactions. Tests of statistical significance were 2-sided. Statistically significant results denote P values .05.
RESULTS
Of the 3262 patients with CRC, 879 had died by the time of last follow-up, with 451 deaths from CRC. Follow-up ranged from 0 to 10.9 years, with a median of 6.9 years.
Baseline Characteristics
In examining covariates, age, adiposity, BMI, comorbidity, and smoking were inversely related, and MM was directly related, to SMD. White and Hispanic patients had lower SMD compared with black or Asian/Pacific Islander individuals. Proximal cancers were more common among those with low SMD and rectal cancers were more common in those with high SMD. Patients with low SMD were less likely to receive radiotherapy or chemotherapy. Sex and stage of disease were unrelated to SMD (Table 1) . Muscle Radiodensity and Prognosis in CRC/Kroenke et al
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Categorization of SMD
As indicated, analysis of SMD categories (Table 2) as well as spline analysis (Fig. 1 ) each demonstrated that associations between SMD and all-cause as well as CRC-specific mortality were best characterized as a threshold effect. Using optimal stratification, 30,31 sex-specific cutpoints were 32.5 in women and 35.5 in men.
SMD, All-Cause, and CRC-Specific Mortality
The Kaplan-Meier curve (Fig. 2) showed that patients with low SMD had worse overall survival compared with those with normal SMD (log-rank P<.0001). In models adjusted for age, sex, and race, low SMD was associated with elevated risks of CRC-specific and overall mortality. Multivariable adjusted results were qualitatively similar. Compared with those with normal SMD, patients with low SMD demonstrated higher overall (hazard ratio, 1.61; 95% confidence interval, 1.36-1.90) and CRCspecific (hazard ratio, 1.74; 95% confidence interval, 1.38-2.21) mortality (Table 2) .
Cross-Classification of SMD and MM
As was evident in analyses with simultaneous adjustment for SMD and MM, low SMD and sarcopenia (low MM) were each independently associated with higher overall and CRCspecific mortality. In analyses of the cross-classification of SMD and MM, the highest mortality risks were observed in individuals with both low SMD and sarcopenia compared with the reference group (normal SMD/normal MM); this was true in both men and women (Table 3) , and was consistent with an additive, rather than multiplicative, effect (P test for interaction 5 .30).
Stratified Analyses
We noted a stronger association between low SMD and mortality in patients aged <64 years compared with those aged 64 years (P test for interaction 5 .04). We noted a slightly weaker association in patients with stage II disease versus those with stage I and stage III disease (P for interaction 5 .09). There was little evidence of effect modification by sex (Table 4) or other variables (data not shown).
With stratification on grade, stage of disease, and treatment with chemotherapy, proportional hazards assumptions were met. DISCUSSION Consistent with our hypotheses, among patients with CRC, those with low SMD at the time of diagnosis had worse overall and CRC-specific mortality compared with those with normal SMD. Patients with both low SMD and sarcopenia had the highest overall and CRC-specific mortality risks. These findings, derived from what to our knowledge is the largest CRC cohort studied to date with data regarding body composition, provide support that low SMD, as well as phenotypes based on combinations of SMD and MM, are important prognostic factors in patients with CRC.
The results of the current study clarify and represent an advance over findings from previous studies of SMD and prognosis in patients with CRC. [14] [15] [16] [17] [18] Findings in previous studies, which had sample sizes ranging from 67 to 805 patients, have suggested a possible relationship, but these studies have been inconclusive due largely to Original Article 3012 Cancer insufficient power. In fact, in what is the largest previous study to examine SMD and CRC prognosis (805 patients), Malietzis et al found no significant association between myosteatosis (low SMD) and overall or CRC-specific survival, even though risks appeared to be elevated among patients with low SMD. 17 The findings of the current study confirm, and provide strong support for, an association between low SMD and both overall and CRC-specific mortality. The stronger association in younger patients in this population further suggests that low SMD may better differentiate CRC mortality risk in younger versus older patients given that SMD levels decline with age.
In noncancer populations 32, 33 and in patients with cancer, 19, 34 low SMD promotes higher systemic inflammatory response 16, 19 and insulin resistance. 20, 21 Inflammation and metabolic derangements stimulate tumor cell proliferation, 35, 36 and lead to worse cancer survival. Low SMD also is related to higher postsurgical complications, 14 which are related to elevated CRC mortality. Although this could be due in part to the association with adiposity, which has been associated with poorer wound healing, 37 the independent association between SMD and mortality, adjusted for adiposity, suggests other mechanisms that remain to be explored. 7 As expected, the combination of both low SMD and sarcopenia predicted elevated mortality in patients with CRC, consistent with an additive effect. Sarcopenia has been predictive of higher mortality in many cancers, including CRC, as was observed in our recent study. 23 Sarcopenia also has been related to higher systemic inflammatory response, 16, 19, 34 metabolic dysregulation, [38] [39] [40] and postsurgical complications, 14 and the effects of each of these muscle abnormalities appear to be independent predictors of outcomes in patients with CRC.
One strength of the current study was the ability to examine body composition parameters at the time of diagnosis before treatment. A great strength was the ability to evaluate associations in a large population-based cohort of 3262 patients with CRC, thereby ensuring sufficient power to examine these associations. Other study strengths include data regarding treatment and comorbidities and follow-up to 10.9 years. A study limitation was that it was not possible to clearly determine whether low SMD influences or is a consequence of tumor progression, although strong associations between SMD at the time of diagnosis and outcomes, even in patients with stage I disease, noted in the current study provide some credence that the effect may not be explained entirely by reverse causation. A possible concern was that the majority of patients (96%) had contrast versus noncontrast scans; SMD levels may be higher in scans with contrast, 41 which could lead to a higher numeric value at which the threshold of low SMD is defined. However, this should not affect the relative ranking of SMD in patients and therefore should not influence overall associations. We also did not have information available regarding optimization of treatment and quality measures such as surgical margins or the extensiveness of lymph node resection. Another potential limitation was the lack of information regarding functional status, which often is included in assessments of sarcopenia in aging populations, although this information typically is not included in the assessment of body composition in cancer populations. Other potential concerns are the inclusion of CT scans obtained months from diagnosis or after surgery. However, when we conducted sensitivity analyses restricted to patients with scans obtained 1 month from diagnosis or to patients with scans obtained before surgery, the results were qualitatively similar (data not shown). An additional limitation, as is true in all observational studies, residual confounding is possible, although we were able to adjust for a larger set of covariates than is possible in the majority of analyses of body composition and cancer outcomes.
In summary, low SMD was found to be associated with elevated all-cause and CRC-specific mortality in a large population of patients with stage I to stage III CRC. Additional studies are needed to understand the mechanisms underlying these results. Nevertheless, body composition markers are prognostic of outcome in patients with CRC and should be incorporated into clinical assessments of patient health status. 
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